In July 2025, HHS Secretary RFK Jr. and FDA Commissioner Dr. Marty Makary announced the FDA's formal recommendation to schedule 7-hydroxymitragynine (7-OH) — a kratom-derived compound — as a Schedule I controlled substance. Seven states already ban kratom outright; Rhode Island in April 2026 became the first to reverse a ban and replace it with a licensed-regulation system. The CDC documented a 1,200% increase in kratom-related poison control exposures over the past decade. In June 2026, NIH launched a Phase 1 clinical trial of kratom's primary alkaloid as a potential treatment for opioid use disorder.

1. Synthetic 7-OH Is the Next Opioid Crisis (RFK Jr.; FDA Commissioner Dr. Marty Makary; Sen. Pete Ricketts)

MAHA's reformers say manufacturers engineered 7-OH for addiction, and it's already in gas stations everywhere.

Synthetic 7-OH isn't kratom — it's a manufactured opioid. Natural dried kratom leaf contains less than 0.04% 7-OH by weight. Manufacturers have concentrated it to more than 100 times that level. The FDA says it can be "up to 13 times more potent than morphine." Makary's position: "7-OH is not just 'like' an opioid — it is an opioid."

RFK Jr. made this personal. At the July 2025 press conference, he drew on his own addiction history: "I became an addict because [heroin] was so available...now you can go to any gas station." The products he's targeting come in candy-flavored gummies and bright-colored packaging. His framing fits MAHA's core argument against the food and supplement industry: corporate products engineered to create dependency, marketed to children.

A bipartisan group of senators went further. Sen. Pete Ricketts (R-NE) and Sen. Richard Blumenthal (D-CT) sent a letter to the FDA in March 2026 calling for scheduling both 7-OH and the whole kratom leaf, calling kratom-derived concentrates "easily accessible and attractive to young Americans."

2. Regulate the Synthetic, Leave the Leaf Alone (Mac Haddow, American Kratom Association; Dr. Kirsten Smith, Johns Hopkins)

Kratom advocates say the crackdown is scientifically sloppy and will punish the people it claims to protect.

The leaf and the concentrate are not the same product. Mac Haddow, Senior Fellow at the American Kratom Association, argues that deaths attributed to "kratom" in toxicology data almost always involve synthetic 7-OH or polydrug use, not the leaf alone. His proposed model: schedule the concentrate, regulate the leaf as a dietary supplement — the same distinction that separates hemp from marijuana.

Scheduling is prohibition with a different name. Dr. Kirsten Smith at Johns Hopkins said plainly: "The term scheduling is kind of a euphemism for what we know it is. It's criminalizing something." She warns against conflating harm reduction potential with synthetic-product dangers — especially with an NIH trial of kratom's primary alkaloid now underway.

The American Kratom Association grew out of personal experience with addiction recovery. Founder Susan Ash began using kratom to escape opioid dependency from Lyme disease treatment. In a survey of more than 6,000 kratom users, 90%+ of those who used it for addiction treatment reported it effective. Ash's position: scheduling the leaf helps pharmaceutical gatekeepers, not the patients who depend on it.

3. The Money Behind the Movement Is Complicated (J.W. Ross, Botanic Tonics; Markwayne Mullin)

Inside the kratom fight, there's a pay-to-play scandal that cuts across both camps.

Botanic Tonics gave $500,000 to a MAHA-aligned PAC. The donation came roughly ten weeks after the DOJ dropped its federal case against the company. CEO J.W. Ross is a former federal prisoner convicted of fraud. His kratom-kava drink, "Feel Free," is available in roughly 24,000 retail locations.

Mullin condemned kratom while reportedly holding an undisclosed Botanic Tonics stake. Homeland Security Secretary Markwayne Mullin has not publicly addressed the reported stake. Major news organizations have not independently confirmed the claim; it comes primarily from opinion journalism. If accurate, it represents a conflict of interest that complicates both sides of the debate.

Where This Lands

RFK Jr. and the FDA see this as a consumer protection fight — synthetic 7-OH is an engineered opioid sold without prescription, and the MAHA movement exists to stop exactly this kind of corporate exploitation of health. The American Kratom Association and researchers like Dr. Smith see a blunter instrument threatening a plant with real medical applications at the same moment NIH is finally studying it. The money story — a $500K donation and an undisclosed financial stake — makes it harder for either side to claim clean hands.

Sources